iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives

Overall survival benefit reached statistical significance in the IORT group with tumors less than or equal to 2.5 cm³ (p<0.05)

NASHUA, N.H., May 13, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced positive new clinical data supporting the Xoft Axxent Electronic Brachytherapy (eBx) System for the treatment of glioblastoma multiforme (GBM) will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, which will take place May 29-31, 2020.

“This represents a significant milestone for the company, as it further validates Xoft intraoperative radiation therapy (IORT) in certain types of brain tumors and demonstrates the impact that this unique technology offers,” according to Michael Klein, Chairman and CEO of iCAD. “GBM is the most common and aggressive type of malignant primary brain tumor, with a median survival of 10-12 months.^1,2 With almost 297,000 cases of brain and nervous system tumors diagnosed worldwide per year,³ this exciting new application for the Xoft System could substantially expand our addressable market, but more importantly, it has the potential to extend patients’ lives.”

The study, titled “Intra-operative radiation therapy as salvage treatment option for recurrent glioblastoma multiforme,” (abstract #291893) was submitted to ASCO by Nidal Salim, MD, radiation oncologist and head of the radiotherapy center at the European Medical Center (EMC) in Moscow, one of the largest private medical clinics in Russia and an international leader in comprehensive care and oncology. It involved 30 patients with recurrent GBM who were treated between August 2016 and June 2019. All patients underwent maximal safe resection; 15 patients were treated with IORT without adjunctive chemotherapy, while the other 15 were treated with external beam radiation therapy (EBRT) and temozolomide. According to study findings, as of December 2019, median overall survival (OS) was 27 months in the IORT group, versus 21 months in the EBRT group. The local progression free survival (locPFS) range for the IORT group was between 3.5 to 39 months, versus 2 to 10 months in the EBRT group. As of December 2019, 8 patients from the IORT group were still alive, whereas none of the patients in the EBRT group survived. Kaplan-Meier OS curves in patients with post-operative contrast-enhancing volume (POCEV) of ≤ 2.5cm³ showed more favorable outcomes for patients in the IORT group (p < 0.05). Researchers concluded that IORT of recurrent GBM is feasible and provides encouraging local progression-free and overall survival, with a manageable toxicity profile.